Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight ...

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ...

SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...

Shanghai: Amgen's lung cancer drug tarlatamab has won approval from ​China's National Medical Products Administration, its ...

The trial compares two active regimens of pegloticase plus methotrexate, both aimed at hard-to-treat gout that does not respond to standard drugs. One arm uses 16 mg of pegloticase by IV every four ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Amgen (AMGN) stock climbs as MariTide GLP-1 trials demonstrate nearly 20% weight loss. Truist raises price target to $325 ...

The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...